Author: KEI Staff

Today Gilead announced it will provide seven generic drug manufacturers licenses to make and sell two drugs that are used in combination to treat the Hepatitis C Virus (HCV) in 91 developing countries.

Continue Reading →

As part of a partial response to FOIA request, USTR has provided KEI with copies of 13 letters sent by members of Congress, from July 27, 2011 to August 8, 2013, on the topic of biologic drug test data provisions in the TPP negotiation. We had obtained several but not all of these letters earlier from a variety of sources, including from PhRMA’s web page — where some had been proudly displayed. (See link below).

Were there letters on the other side? Yes, three. (see below).

With the FOIA request, we have also obtained the responses to the letters.

Continue Reading →

KEI’s Additional Comments Special 301

March 7, 2014

James Love, Knowledge Ecology International

Docket # USTR-2013-0040

These comments supplement KEI’s February 7, 2014 written submission (Also available here: https://www.keionline.org/ustr/special301, and /node/1927), and our February 24, 2014 oral testimony, and provide also comment or reply to the written or oral submissions by others.

1. India is an important source of affordable medicines.

Continue Reading →

The KEI written statement for the February 14, 2014 US International Trade Commission (USITC) hearing on India is attached here.

Among other things, the Statement includes 15 pages describing US compulsory licenses.

We also have a video play list with more than 9 hours of the Feb 12 and Feb 14 hearing.

http://www.youtube.com/playlist?list=PLLw9jWaZPEpwU_euETpPaVjdcFpKlCxp-
Continue Reading →

Claire Cassedy did this interview at the KEI offices, following the February 24, 2014 USTR hearing on the Special 301.
Continue Reading →